Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension

Hypertension

Volumn 57, Issue 2, 2011, Pages 308-313

  Matavelli, Luis C ^a   Huang, Jiqian ^a   Siragy, Helmy M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

angiotensin receptor; cytokines; inflammation; kidney; renin angiotensin system; renovascular hypertension

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CYCLIC GMP; INTERLEUKIN 6; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; N BUTYLOXYCARBONYL 3 (4 IMIDAZOL 1 YLMETHYLPHENYL) 5 ISOBUTYLTHIOPHENE 2 SULFONAMIDE; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONA MIDE; PYRIDINE DERIVATIVE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; INFLAMMATION; INTERSTITIAL FLUID; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ANIMAL; BLOOD PRESSURE; BODY WEIGHT; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; GENETICS; KIDNEY; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; BODY WEIGHT; CYCLIC GMP; GENE EXPRESSION; HYPERTENSION, RENOVASCULAR; IMIDAZOLES; INFLAMMATION; INTERLEUKIN-6; KIDNEY; MALE; NITRIC OXIDE; ORGAN SIZE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; THIOPHENES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551505061     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.164202     Document Type: Article

References (37)

1. Siragy HM. The angiotensin II type 2 receptor and the kidney. J Renin Angiotensin Syst. 2010;11:33-36.
2. Morrissey JJ, Klahr S. Effect of AT2 receptor blockade on the patho-genesis of renal fibrosis. Am J Physiol Renal Physiol. 1999;276:F39-F45.
3. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 1997;30:1238-1246.
4. Miyata N, Park F, Li XF, Cowley AW Jr. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol Renal Physiol. 1999;277:F437-F446.
5. Lerman LO, Textor SC, Grande JP. Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond. Prog Cardiovasc Dis. 2009;52: 196-203.
6. Ferreri NR, Escalante BA, Zhao Y, An SJ, McGiff JC. Angiotensin II induces TNF production by the thick ascending limb: functional implications. Am J Physiol Renal Physiol. 1998;274:F148-F155.
7. Wolf G, Schneider A, Wenzel U, Helmchen U, Stahl RA. Regulation of glomerular TGF-beta expression in the contralateral kidney of two-kidney, one-clip hypertensive rats. J Am Soc Nephrol. 1998;9:763-772.
8. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol. 2003;285:R117-R124.
9. Siragy HM, Inagami T, Carey RM. NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1461-R1467.
10. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264-269.
11. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension. 2003;42:600-604.
12. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M, Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001;104:2716-2721.
13. Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA. 1999;96:6506-6510.
14. Hu C, Dandapat A, Chen J, Liu Y, Hermonat PL, Carey RM, Mehta JL. Over-expression of angiotensin II type 2 receptor (agtr2) reduces athero-genesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis. 2008;199:288-294.
15. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008.
16. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlöf B, Kintscher U, Unger T, Steckelings UM. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523-2532.
17. Gelosa P, Pignieri A, Fändriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, Sironi L. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444-2451.
18. Rompe F, Artuc M, Hallberg A, Alterman M, Ströder K, Thöne-Reineke C, Reichenbach A, Schacherl J, Dahlöf B, Bader M, Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck WH, Unger T, Steckelings UM. Direct angiotensin II type 2 receptor stimu lation acts anti-inflammatory through epoxyeicosatrienoic acid and inhi bition of nuclear factor kappaB. Hypertension. 2010;55:924-931.
19. Huang J, Siragy HM. Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. Endocrinology. 2009;150:5557-5565.
20. Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD. Unraveling the mystery of Goldblatt hypertension. News Physiol Sci. 1998;13:170-176.
21. Chade AR, Rodriguez-Porcel M, Grande JP, Krier JD, Lerman A, Romero JC, Napoli C, Lerman LO. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation. 2002;106:1165-1171.
22. Tanaka M, Tsuchida S, Imai T, Fujii N, Miyazaki H, Ichiki T, Naruse M, Inagami T. Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 knockout mice. Biochem Biophys Res Commun. 1999;258:194-198.
23. Modrall JG, Quinones MJ, Frankhouse JH, Hsueh WA, Weaver FA, Kedes L. Upregulation of angiotensin II type 1 receptor gene expression in chronic renovascular hypertension. J Surg Res. 1995;59:135-140.
24. Hiyoshi H, Yayama K, Takano M, Okamoto H. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension. 2004;43:1258-1263.
25. Hiyoshi H, Yayama K, Takano M, Okamoto H. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension. 2005;45:967-973.
26. Wang ZQ, Millatt LJ, Heiderstadt NT, Siragy HM, Johns RA, Carey RM. Differential regulation of renal angiotensin subtype AT1A and AT2 receptor protein in rats with angiotensin-dependent hypertension. Hypertension. 1999; 33:96-101.
27. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292-316.
28. Ruiz-Ortega M, Esteban V, Suzuki Y, Ruperez M, Mezzano S, Ardiles L, Justo P, Ortiz A, Egido J. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl. 2003;86:S21-S26.
29. Shibata K, Makino I, Shibaguchi H, Niwa M, Katsuragi T, Furukawa T. Up-regulation of angiotensin type 2 receptor mRNA by angiotensin II in rat cortical cells. Biochem Biophys Res Commun. 1997;239:633-637.
30. Zahradka P, Yau L, Lalonde C, Buchko J, Thomas S, Werner J, Nguyen M, Saward L. Modulation of the vascular smooth muscle angiotensin subtype 2 (AT2) receptor by angiotensin II. Biochem Biophys Res Commun. 1998;252:476-480.
31. De Paolis P, Porcellini A, Gigante B, Giliberti R, Lombardi A, Savoia C, Rubattu S, Volpe M. Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells. J Hypertens. 1999;17:1873-1877.
32. Ozawa Y, Kobori H, Suzaki Y, Navar LG. Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol. 2007;292:F330-F339.
33. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288-296.
34. Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, Han JY, Kon V, Fogo AB. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol. 2010;298:F683-F691.
35. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: 861-869.
36. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension. 2004;44:248-252.
37. 1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest. 1996;97:1978-1982.